KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Return on Invested Capital (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Return on Invested Capital for 11 consecutive years, with 0.67% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Invested Capital fell 78.0% to 0.67% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.67%, a 78.0% decrease, with the full-year FY2025 number at 0.09%, down 15.0% from a year prior.
  • Return on Invested Capital was 0.67% for Q4 2025 at Supernus Pharmaceuticals, down from 0.06% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.15% in Q1 2021 to a low of 0.67% in Q4 2025.
  • A 5-year average of 0.01% and a median of 0.05% in 2025 define the central range for Return on Invested Capital.
  • Peak YoY movement for Return on Invested Capital: increased 11bps in 2024, then tumbled -78bps in 2025.
  • Supernus Pharmaceuticals' Return on Invested Capital stood at 0.06% in 2021, then crashed by -31bps to 0.04% in 2022, then tumbled by -106bps to 0.0% in 2023, then soared by 4427bps to 0.11% in 2024, then crashed by -711bps to 0.67% in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Return on Invested Capital are 0.67% (Q4 2025), 0.06% (Q3 2025), and 0.05% (Q2 2025).